101
|
Abstract
Serotonin syndrome (SS) and neuroleptic malignant syndrome (NMS) are two rare, but serious adverse reactions associated with psychotropic medications. While the disorders may share certain features, there are differences in how they are managed and treated. This article reviews the risk factors, clinical presentation, and treatment of SS and NMS.
Collapse
|
102
|
Abstract
Neuroleptic malignant syndrome (NMS) is a life-threatening idiosyncratic reaction to antipsychotic drugs characterized by fever, altered mental status, muscle rigidity, and autonomic dysfunction. It has been associated with virtually all neuroleptics, including newer atypical antipsychotics, as well as a variety of other medications that affect central dopaminergic neurotransmission. Although uncommon, NMS remains a critical consideration in the differential diagnosis of patients presenting with fever and mental status changes because it requires prompt recognition to prevent significant morbidity and death. Treatment includes immediately stopping the offending agent and implementing supportive measures, as well as pharmacological interventions in more severe cases. Maintaining vigilant awareness of the clinical features of NMS to diagnose and treat the disorder early, however, remains the most important strategy by which physicians can keep mortality rates low and improve patient outcomes.
Collapse
Affiliation(s)
- Brian D Berman
- Department of Neurology, University of Colorado Denver School of Medicine, Aurora, CO, USA
| |
Collapse
|
103
|
Neuroleptic malignant syndrome in a patient with tongue cancer: a report of a rare case. Case Rep Dent 2013; 2013:542130. [PMID: 23853728 PMCID: PMC3703349 DOI: 10.1155/2013/542130] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2013] [Accepted: 05/26/2013] [Indexed: 11/17/2022] Open
Abstract
Background. Neuroleptic malignant syndrome (NMS) is a rare but life-threatening complication of neuroleptic drugs, which are used widely in head and neck cancer (HANC) patients who develop delirium. Methods and Results. Postoperative delirium in a 39-year-old man with tongue cancer was treated with haloperidol and chlorpromazine. Three days after the first administration of antipsychotics, the patient exhibited elevated body temperature, autonomic and extrapyramidal symptoms, and impaired consciousness. A definitive diagnosis was made using the research diagnostic criteria for NMS in the DSM-IV, and the antipsychotics were immediately discontinued. The patient was given dantrolene and bromocriptine to treat the NMS. The patient's hyperthermia, elevated creatinin kinase (CK), and muscle rigidity improved gradually, with all symptoms of NMS resolving completely by 13 days after the diagnosis. Conclusions. HANC surgeons must be alert for early signs of NMS and use antipsychotics conservatively to avoid NMS and its potentially fatal outcome.
Collapse
|
104
|
Dixit D, Shrestha P, Adelman M. Neuroleptic malignant syndrome associated with haloperidol use in critical care setting: should haloperidol still be considered the drug of choice for the management of delirium in the critical care setting? BMJ Case Rep 2013; 2013:bcr-2013-010133. [PMID: 23853022 DOI: 10.1136/bcr-2013-010133] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Abstract
A 48-year-old man was brought to the emergency department because of intoxication. The patient was in respiratory distress, subsequently intubated for airway protection. On hospital day 5, he was diagnosed with delirium. Haloperidol was initiated at 5 mg intravenous every 6 h and titrated up to a dose of 60 mg /day over 5 days. On hospital day 18, his temperature peaked to 107.1°F. Other symptoms included mental status change, muscular rigidity and autonomic dysfunction. Neuroleptic malignant syndrome (NMS) associated with haloperidol was suspected. No other causes for these symptoms were present. Concurrent medications were reviewed and ruled out for possible drug-induced fever. Haloperidol was discontinued and dantrolene and bromocriptine was initiated. The temperature decreased to 102.2°F within 3 h and other symptoms resolved overtime. The temporal relationship between the patient's fever decline with the discontinuation of haloperidol, and improvement with dantrolene and bromocriptine, the diagnosis was believed to be haloperidol-induced NMS.
Collapse
Affiliation(s)
- Deepali Dixit
- Department of Pharmacy, Rutgers University, Piscataway, New Jersey, USA.
| | | | | |
Collapse
|
105
|
Neuroleptic malignant syndrome associated with haloperidol treatment in a patient with head injury. FORMOSAN JOURNAL OF SURGERY 2013. [DOI: 10.1016/j.fjs.2013.03.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
|
106
|
Rajesh KM, Sinnathamby V, Sakthi AN. Neuroleptic malignant syndrome masked by cerebral malaria. BMJ Case Rep 2013; 2013:bcr-2013-009061. [PMID: 23704432 DOI: 10.1136/bcr-2013-009061] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Abstract
A 38-year-old man with an underlying psychiatric illness presented with altered sensorium and abnormal behaviour. He was febrile at 38°C and weak looking; otherwise no other abnormalities were detected. A blood film conducted for malarial parasite (BFMP) revealed Plasmodium falciparum; hence a diagnosis of cerebral malaria was made. He was treated with antimalarial drugs for 2 days prior to being transferred out to the ward following clinical improvement. He subsequently developed episodes of stupor and refusal of feeding. Following an evaluation by the psychiatrist, a diagnosis of catatonic schizophrenia was made and he was started on oral sulpiride and benhexol. Unfortunately, he developed high-grade fever at 40°C with muscle rigidity and fasciculation. The diagnosis of neuroleptic malignant syndrome (NMS) was clinched and the antipsychotics were discontinued. However he succumbed to NMS several days later due to multiorgan failure.
Collapse
Affiliation(s)
- Kumar Muniandy Rajesh
- Medicine Based Department, School of Medicine, Universiti Malaysia Sabah, Kota Kinabalu, Sabah, Malaysia.
| | | | | |
Collapse
|
107
|
Sa YK, Yang H, Jung HK, Son JW, Lee SS, Kim SR, Cha BY, Son HY, Pae CU, Yoo SJ. Olanzapine-induced diabetic ketoacidosis and neuroleptic malignant syndrome with rhabdomyolysis: a case report. Endocrinol Metab (Seoul) 2013; 28:70-5. [PMID: 24396655 PMCID: PMC3811799 DOI: 10.3803/enm.2013.28.1.70] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/01/2012] [Accepted: 07/06/2012] [Indexed: 11/11/2022] Open
Abstract
Atypical antipsychotics have replaced conventional antipsychotics in the treatment of schizophrenia because they have less of a propensity to cause undesirable neurologic adverse events including extrapyramidal symptoms, tardive dyskinesia, and neuroleptic malignant syndrome (NMS). However, atypical antipsychotics have been known to result in various metabolic complications such as impaired glucose tolerance, diabetes and even diabetic ketoacidosis (DKA). In addition, a number of NMS cases have been reported in patients treated with atypical antipsychotics, although the absolute incidence of neurologic side effects is currently significantly low. Here, we report a patient who simultaneously developed DKA, acute renal failure and NMS with rhabdomyolysis after olanzapine treatment. Olanzapine-induced metabolic complications and NMS were dramatically improved with cessation of the olanzapine treatment and initiation of supportive management including fluid therapy, hemodialysis, and intensive glycemic control using insulin. At short-term follow-up, insulin secretion was markedly recovered as evidenced by a restoration of serum C-peptide level, and the patient no longer required any hypoglycemic medications. Despite the dramatic increase in the use of atypical antipsychotics treatment, individualized treatments along with careful monitoring may be prudent for high risk or vulnerable patients in order to avoid the development of metabolic side effects.
Collapse
Affiliation(s)
- Young Kyoung Sa
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Bucheon St. Mary's Hospital, The Catholic University of Korea College of Medicine, Bucheon, Korea
| | - Hyeon Yang
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Bucheon St. Mary's Hospital, The Catholic University of Korea College of Medicine, Bucheon, Korea
| | - Hee Kyoung Jung
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Bucheon St. Mary's Hospital, The Catholic University of Korea College of Medicine, Bucheon, Korea
| | - Jang Won Son
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Bucheon St. Mary's Hospital, The Catholic University of Korea College of Medicine, Bucheon, Korea
| | - Seong Su Lee
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Bucheon St. Mary's Hospital, The Catholic University of Korea College of Medicine, Bucheon, Korea
| | - Seong Rae Kim
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Bucheon St. Mary's Hospital, The Catholic University of Korea College of Medicine, Bucheon, Korea
| | - Bong Yeon Cha
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Korea
| | - Ho Young Son
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Korea
| | - Chi-Un Pae
- Department of Psychiatry, Bucheon St. Mary's Hospital, The Catholic University of Korea College of Medicine, Bucheon, Korea
| | - Soon Jib Yoo
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Bucheon St. Mary's Hospital, The Catholic University of Korea College of Medicine, Bucheon, Korea
| |
Collapse
|
108
|
Pilgrim JL, Drummer OH. The toxicology and comorbidities of fatal cases involving quetiapine. Forensic Sci Med Pathol 2013; 9:170-6. [PMID: 23397562 DOI: 10.1007/s12024-012-9404-4] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/19/2012] [Indexed: 11/26/2022]
Abstract
The use of quetiapine in Australia has increased rapidly in recent years. Anecdotal and post-marketing surveillance reports indicate an increase in quetiapine misuse in prisons as well as an increase in its availability on the black-market. This study examined a cohort of quetiapine-associated deaths occurring in Victoria, Australia, between 2001 and 2009, to determine the prevalence of deaths associated with this drug and to determine whether misuse represents a legitimate concern. Case details were extracted from the National Coronial Information System. There were 224 cases with an average age of 43 years of age (range 15-87 years). The cause of death was mostly drug toxicity (n = 114, 51 %), followed by natural disease (n = 60, 27 %), external injury (n = 31, 14 %) and unascertained causes (n = 19, 8 %). Depression and/or anxiety were common, observed in over a third of the cohort (80 cases, 36 %). About 20 % of cases did not mention a psychiatric diagnosis at all which raises the question of whether quetiapine had been prescribed correctly in these cases. Cardiovascular disease was the most commonly reported illness after mental disease. Quetiapine ranged in concentration from the limit of reporting (0.01 mg/L) to 110 mg/L. The median concentration of quetiapine was much lower in the natural disease deaths (0.25 mg/L) compared with drug caused deaths (0.7 mg/L). The most commonly co-administered drug was diazepam in 81 (36 %) cases. There were a small number of cases where quetiapine contributed to a death where it had not apparently been prescribed, including the death of a 15 year old boy and one of a 34 year old female. Overall, misuse of quetiapine did not appear to be a significant issue in this cohort; use of the drug only occasionally led to fatalities when used in excess or concomitantly with interacting drugs. However, considering that it is a recent social concern, it is possible that analysis of cases post 2009 would reveal more cases of quetiapine abuse. Close monitoring of quetiapine is therefore advised to prevent adverse outcomes, particularly in vulnerable populations such as substance abusers.
Collapse
Affiliation(s)
- Jennifer L Pilgrim
- Department of Forensic Medicine, Monash University, 57-83 Kavanagh Street, Southbank, VIC, 3006, Australia.
| | | |
Collapse
|
109
|
Nisijima K, Shioda K. Temporal changes in serum creatine kinase concentration and degree of muscle rigidity in 24 patients with neuroleptic malignant syndrome. Neuropsychiatr Dis Treat 2013; 9:853-9. [PMID: 23818785 PMCID: PMC3692345 DOI: 10.2147/ndt.s45084] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Neuroleptic malignant syndrome (NMS) is a dangerous adverse response to antipsychotic drugs. It is characterized by the four major clinical symptoms of hyperthermia, severe muscle rigidity, autonomic dysfunction, and altered mental state. Serum creatine kinase (CK) elevation occurs in over 90% of NMS cases. In the present study, the detailed temporal changes in serum CK and degree of muscle rigidity, and the relationship between CK concentration and degree of muscle rigidity over the time course from fever onset, were evaluated in 24 affected patients. The results showed that serum CK peaked on day 2 after onset of fever and returned to within normal limits at day 12. Mild muscle rigidity was observed before the onset of fever in 17 of 24 cases (71%). Muscle rigidity was gradually exacerbated and worsened until day 4 after onset of fever. These findings confirm physicians' empirical understanding of serum CK concentrations and muscle rigidity in NMS based on data accumulated from numerous patients with the syndrome, and they indicate that serum CK may contribute to the early detection of NMS.
Collapse
Affiliation(s)
- Koichi Nisijima
- Department of Psychiatry, Jichi Medical University, Tochigi, Japan
| | | |
Collapse
|
110
|
Abstract
We present the history of four bipolar patients who developed neuroleptic malignant syndrome (NMS) after antipsychotic treatment, focusing on the relationship between NMS and catatonia. In all cases, the administration of antipsychotics has been suspended as soon as fever and autonomic disturbances occurred. A supportive therapy was initiated to stabilize general conditions, then every patient started electroconvulsive therapy (ECT) in combination with benzodiazepines (BDZ). The risk of complications was reduced by the quick adoption of supportive care, whereas the combination of ECT and BDZ was effective in resolving the clinical picture. These cases may provide further support to the hypothesis that catatonia and NMS are disorders pertaining to the same spectrum of illness because the onset or exacerbation of catatonic symptoms coincided with the administration of antipsychotics. Our experience confirms the efficacy and safety of ECT in combination with BDZ as treatment of NMS and residual catatonia.
Collapse
|
111
|
Langan J, Martin D, Shajahan P, Smith DJ. Antipsychotic dose escalation as a trigger for neuroleptic malignant syndrome (NMS): literature review and case series report. BMC Psychiatry 2012; 12:214. [PMID: 23194104 PMCID: PMC3546951 DOI: 10.1186/1471-244x-12-214] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/08/2012] [Accepted: 11/27/2012] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND "Neuroleptic malignant syndrome" (NMS) is a potentially fatal idiosyncratic reaction to any medication which affects the central dopaminergic system. Between 0.5% and 1% of patients exposed to antipsychotics develop the condition. Mortality rates may be as high as 55% and many risk factors have been reported. Although rapid escalation of antipsychotic dose is thought to be an important risk factor, to date it has not been the focus of a published case series or scientifically defined. DESCRIPTION We aimed to identify cases of NMS and review risk factors for its development with a particular focus on rapid dose escalation in the 30 days prior to onset. A review of the literature on rapid dose escalation was undertaken and a pragmatic definition of "rapid dose escalation" was made. NMS cases were defined using DSM-IV criteria and systematically identified within a secondary care mental health service. A ratio of titration rate was calculated for each NMS patient and "rapid escalators" and "non rapid escalators" were compared. 13 cases of NMS were identified. A progressive mean dose increase 15 days prior to the confirmed episode of NMS was observed (241.7 mg/day during days 1-15 to 346.9 mg/day during days 16-30) and the mean ratio of dose escalation for NMS patients was 1.4. Rapid dose escalation was seen in 5/13 cases and non rapid escalators had markedly higher daily cumulative antipsychotic dose compared to rapid escalators. CONCLUSIONS Rapid dose escalation occurred in less than half of this case series (n = 5, 38.5%), although there is currently no consensus on the precise definition of rapid dose escalation. Cumulative antipsychotic dose - alongside other known risk factors - may also be important in the development of NMS.
Collapse
Affiliation(s)
- Julie Langan
- Institute of Health an Wellbeing, Mental Health and Wellbeing, Gartnavel Royal Hospital, University of Glasgow, 1055 Great Western Road, Glasgow, G12 0XH, Scotland, UK
| | - Daniel Martin
- Institute of Health an Wellbeing, Mental Health and Wellbeing, Gartnavel Royal Hospital, University of Glasgow, 1055 Great Western Road, Glasgow, G12 0XH, Scotland, UK
| | - Polash Shajahan
- NHS Lanarkshire, Greenmoss Community Health centre, University of Glasgow, Greenmoss Place, Bellshill, ML4 1PS, Scotland, UK
| | - Daniel J Smith
- Institute of Health an Wellbeing, Mental Health and Wellbeing, Gartnavel Royal Hospital, University of Glasgow, 1055 Great Western Road, Glasgow, G12 0XH, Scotland, UK
| |
Collapse
|
112
|
Abstract
A clinical and biological pattern similar to that of neuroleptic malignant syndrome is reported in a depressed patient treated with trimipramine, without any concomitant use of neuroleptics. The antidopaminergic properties of this drug, one of the tricyclic antidepressants, may account for this uncommon side effect.
Collapse
Affiliation(s)
- M Abbar
- Service de Psychologie Médicale, Hôpital Lapeyronie, 34059 Montpellier, France
| | | | | |
Collapse
|
113
|
Matheson KM, Gray G. Clozapine-induced neuroleptic malignant syndrome in an adolescent. J Child Adolesc Psychopharmacol 2012; 22:322-4. [PMID: 22897669 DOI: 10.1089/cap.2011.0131] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Affiliation(s)
| | - Gerald Gray
- Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia, Canada
- Izaak Walton Killam Health Centre, Halifax, Nova Scotia, Canada
| |
Collapse
|
114
|
Lithium toxicity and neurologic effects: probable neuroleptic malignant syndrome resulting from lithium toxicity. Case Rep Psychiatry 2012; 2012:271858. [PMID: 22953147 PMCID: PMC3420417 DOI: 10.1155/2012/271858] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2012] [Accepted: 02/28/2012] [Indexed: 12/02/2022] Open
Abstract
Introduction. We present the case of a patient who developed lithium toxicity with normal therapeutic levels, as a result of pharmacokinetic interaction with Valsartan, and probable Neuroleptic Malignant Syndrome from the ensuing lithium toxicity. Case Presentation. A 59-year old black male with bipolar disorder maintained on lithium and fluphenazine therapy presented with a 2 week history of worsening confusion, tremor, and gait abnormality. He recently had his dose of Valsartan increased. At presentation, patient had signs of autonomic instability, he was confused, dehydrated, and had rigidity of upper extremities. Significant labs on admission were lithium level-1.2, elevated CK-6008, leukocytosis WBC-22, and renal impairment; Creatinine-4.1, BUN-35, HCO3-20.1, and blood glucose 145. CT/MRI brain showed old cerebral infarcts, and there was no evidence of an infective process. Lithium and fluphenazine were discontinued, his lithium levels gradually decreased, and he improved with supportive treatment including rehydration and correction of electrolyte imbalance. Conclusions. This case illustrates that lithium toxicity can occur within therapeutic levels, and the neurotoxic effect of lithium can include Neuroleptic Malignant Syndrome. Clinicians should be aware of the risk associated with drug interactions with lithium.
Collapse
|
115
|
Chang CK, Harrison S, Lee W, Taylor D, Stewart R. Ascertaining instances of neuroleptic malignant syndrome in a secondary mental healthcare electronic medical records database: the SLAM BRC Case Register. Ther Adv Psychopharmacol 2012; 2:75-83. [PMID: 23983959 PMCID: PMC3736931 DOI: 10.1177/2045125312438215] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
OBJECTIVES Neuroleptic malignant syndrome (NMS) is a rare but potentially fatal complication of antipsychotic treatment. However, there is no single diagnostic test and a variety of overlapping criteria exist. Using a large case register of secondary mental healthcare in Southeast London, we aimed to identify suspected cases and quantify the levels of agreement between six different diagnostic criteria previously published. METHODS Taking advantage of a recently developed case register sourced from full but anonymized electronic medical records (the South London and Maudsley NHS Foundation Trust), we applied text string searching to identify suspected NMS cases for which action had been taken to investigate or treat. Three psychiatrists manually reviewed case records for clinical data to compare diagnostic criteria. RESULTS Analysis of the case register revealed 183 suspected NMS cases, of which 43 fulfilled at least one set of the six diagnostic criteria. Agreement between criteria was poor (κ = 0.35 for all combined agreement; 95% confidence interval 0.31-0.39) and only one case fulfilled all six diagnostic criteria. However, among cases meeting any diagnostic criteria, pyrexia, extrapyramidal symptoms, altered consciousness, autonomic symptoms, and elevated CK concentrations were significantly more common than in cases not meeting diagnostic criteria (p < 0.01). On further analyses, the presence of two or more of these features significantly distinguished cases meeting criteria from those that did not (p < 0.01). Individual symptoms were also reported in suspected cases of NMS that did not fulfil any diagnostic criteria. CONCLUSIONS In a large sample of NMS cases recorded in medical records, relatively poor agreement was found among published diagnostic criteria for NMS. However, core features of NMS were observed significantly more often among cases meeting diagnostic criteria. Individual symptoms were also described in suspected cases that did not meet diagnostic criteria. These findings suggest a continued need for consensus on standard criteria for NMS.
Collapse
|
116
|
|
117
|
Nisijima K. Elevated creatine kinase does not necessarily correspond temporally with onset of muscle rigidity in neuroleptic malignant syndrome: a report of two cases. Neuropsychiatr Dis Treat 2012; 8:615-8. [PMID: 23271911 PMCID: PMC3526146 DOI: 10.2147/ndt.s38638] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/03/2022] Open
Abstract
Neuroleptic malignant syndrome is an uncommon but dangerous complication of antipsychotic drugs, characterized by clinical symptoms that include hyperthermia, severe muscle rigidity, autonomic dysfunction, and altered mental state. Serum creatine kinase (CK) elevation occurs in over 90% of cases. Many diagnostic criteria sets for neuroleptic malignant syndrome have been proposed, all of which include hyperthermia and muscle rigidity as major symptoms, and serum CK elevation as either a major or minor symptom. In general, elevated CK occurs in the initial stage of neuroleptic malignant syndrome and corresponds temporally with the onset of muscle rigidity. However, in some exceptional cases, CK elevation and emergence of muscle rigidity do not appear in the same stage, making early diagnosis of neuroleptic malignant syndrome more difficult. Two rare cases of neuroleptic malignant syndrome are presented in which elevated serum CK and emergence of muscle rigidity did not occur in the same stage of neuroleptic malignant syndrome. An elevated CK level is common in the early stage of neuroleptic malignant syndrome, suggesting that serum CK elevation is a useful indicator for early detection of neuroleptic malignant syndrome. However, a definitive diagnosis of neuroleptic malignant syndrome must be determined from the presence of specific clinical symptoms.
Collapse
Affiliation(s)
- Koichi Nisijima
- Department of Psychiatry, Jichi Medical University, Tochigi, Japan
| |
Collapse
|
118
|
Molina D, Tingle LE, Lu X. Aripiprazole as the causative agent of neuroleptic malignant syndrome: a case report. PRIMARY CARE COMPANION TO THE JOURNAL OF CLINICAL PSYCHIATRY 2011; 9:148-50. [PMID: 17607339 PMCID: PMC1896300 DOI: 10.4088/pcc.v09n0211b] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
119
|
Ioos V, Das V, Maury E, Baudel JL, Guéchot J, Guidet B, Offenstadt G. A thyrotoxicosis outbreak due to dietary pills in Paris. Ther Clin Risk Manag 2011; 4:1375-9. [PMID: 19337445 PMCID: PMC2643119 DOI: 10.2147/tcrm.s4110] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
Abstract
Three women were consecutively admitted to our medical intensive care unit for thyrotoxicosis after the ingestion of dietary pills accidentally containing high levels of thyroxin. These cases were observed during an outbreak in the Paris area. Despite similar blood levels of thyroid hormones, their clinical presentation and outcome were very different. One patient developed febrile confusion and died from malignant hyperthermia. The second one had progressive confusion requiring mechanical plasma exchange therapy and had a favorable outcome. The third one had very moderate symptoms. These exceptional observations raise several issues concerning diagnosis, physiopathology and treatment of thyrotoxicosis factitia.
Collapse
|
120
|
Moscovich M, Nóvak FT, Fernandes AF, Bruch T, Tomelin T, Nóvak EM, Munhoz RP, Teive HA. Neuroleptic malignant syndrome. ARQUIVOS DE NEURO-PSIQUIATRIA 2011; 69:751-5. [DOI: 10.1590/s0004-282x2011000600005] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/01/2011] [Accepted: 05/31/2011] [Indexed: 11/21/2022]
Abstract
Neuroleptic malignant syndrome (NMS) is a potentially fatal adverse event associated with the use of antipsychotics (AP). The objective of this study was to investigate the profile of cases of NMS and to compare our findings with those published in similar settings. A series of 18 consecutive patients with an established diagnosis of NMS was analyzed, gathering data on demography, symptoms and signs. Two thirds of all cases involved woman with a past medical history of psychiatric disorder receiving relatively high doses of AP. The signs and symptoms of NMS episodes were similar to those reported in other series and only one case had a fatal outcome, the remaining presenting complete recovery. As expected, more than two thirds of our cases were using classic AP (68%), however the clinical profile of these in comparison with those taking newer agent was similar. Newer AP also carry the potential for NMS.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Renato P. Munhoz
- Pontifical Catholic University of Paraná, Brazil; Federal University of Paraná, Brazil
| | | |
Collapse
|
121
|
Ramamoorthy KG, Downey H, Hawthorne P. Rocuronium and sugammadex: An alternative to succinylcholine for electro convulsive therapy in patients with suspected neuroleptic malignant syndrome. J Anaesthesiol Clin Pharmacol 2011; 27:380-2. [PMID: 21897513 PMCID: PMC3161467 DOI: 10.4103/0970-9185.83687] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
We report a case of presumptive neuroleptic malignant syndrome requiring muscle relaxation for electro-convulsive therapy. short acting muscle relaxation without the use of succinylcholine was achieved using rocvronivm reversed with the novel reversal agent sugammadex. We suggest that this combination is a safe and effective alternative to succinylcholine in such cases.
Collapse
Affiliation(s)
- Karthik G Ramamoorthy
- Department of Anaesthesia, Consultant, Letterkenny General Hospital, Letterkenny, Ireland
| | | | | |
Collapse
|
122
|
Arslankoylu AE, Kutuk MO, Okuyaz C, Toros F. Neuroleptic malignant syndrome due to risperidone misdiagnosed as status epilepticus. Pediatr Rep 2011; 3:e19. [PMID: 22053263 PMCID: PMC3207307 DOI: 10.4081/pr.2011.e19] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/27/2011] [Accepted: 06/21/2011] [Indexed: 11/23/2022] Open
Abstract
Neuroleptic malignant syndrome (NMS) is a rare but potentially fatal disease characterized by fever, muscle rigidity, delirium and autonomic instability. Here we report a child, with NMS due to the risperidone misdiagnosed as status epilepticus. Nine year old boy, who had been under high dose risperidone treatment for 8 weeks, admitted to the emergency room because of the contractions (evaluated as status epilepticus) persisting for 7 hours. Since there was neuroleptic treatment in the past medical history and, unconsciousness, muscular rigidity, diaphoresis, hypertermi and, hypotension in physical examination, leucocytosis and elevated creatininphosphokinase levels in laboratory tests, the patient was evaluated as NMS and discharged without any complications. We reported this case to point out that; NMS may be misdiagnosed as status epilepticus in children when EEG monitoring is unavailable. When a child admitted to the emergency room because of suspicious convulsion neuroleptic drug use must surely be asked.
Collapse
Affiliation(s)
- Ali Ertug Arslankoylu
- Mersin University Faculty of Medicine, Department of Pediatrics, Pediatric Intensive Care Unit, Mersin, Turkey
| | | | | | | |
Collapse
|
123
|
Neuroleptic malignant syndrome with metoclopramide overdose coexisting with Clostridium difficile diarrhea. Intensive Care Med 2011; 37:1706-8. [DOI: 10.1007/s00134-011-2250-0] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/02/2011] [Indexed: 11/27/2022]
|
124
|
Choi HD, Kim KK, Koo BH. A case of catatonia and neuroleptic malignant syndrome probably associated with antipsychotic in Korea. Psychiatry Investig 2011; 8:174-7. [PMID: 21852996 PMCID: PMC3149114 DOI: 10.4306/pi.2011.8.2.174] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/18/2010] [Revised: 11/29/2010] [Accepted: 12/07/2010] [Indexed: 12/31/2022] Open
Abstract
Several studies have reported on catatonia caused by the use of antipsychotic drugs and on the association between catatonia and neuroleptic malignant syndrome (NMS), but none has reported such a case in Korea. Here, we report the case of a 20-year-old woman whose catatonia and NMS appeared associated with the administration of an atypical antipsychotic drug. We discuss the association between NMS and catatonia due to neuroleptic use.
Collapse
Affiliation(s)
- Ho-Dong Choi
- Department of Psychiatry, Yeungnam University College of Medicine, Daegu, Korea
| | - Kyoung-Keun Kim
- Department of Psychiatry, Yeungnam University College of Medicine, Daegu, Korea
| | - Bon-Hoon Koo
- Department of Psychiatry, Yeungnam University College of Medicine, Daegu, Korea
| |
Collapse
|
125
|
Affiliation(s)
- Paul Howard
- Duchess of Kent House, Reading, United Kingdom
| | | | | | | | | |
Collapse
|
126
|
Caroff SN, Hurford I, Lybrand J, Campbell EC. Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial. Neurol Clin 2011; 29:127-48, viii. [PMID: 21172575 DOI: 10.1016/j.ncl.2010.10.002] [Citation(s) in RCA: 105] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Drug-induced movement disorders have dramatically declined with the widespread use of second-generation antipsychotics, but remain important in clinical practice and for understanding antipsychotic pharmacology. The diagnosis and management of dystonia, parkinsonism, akathisia, catatonia, neuroleptic malignant syndrome, and tardive dyskinesia are reviewed in relation to the decreased liability of the second-generation antipsychotics contrasted with evidence from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial. Data from the CATIE trial imply that advantages of second-generation antipsychotics in significantly reducing extrapyramidal side effects compared with haloperidol may be diminished when compared with modest doses of lower-potency first-generation drugs.
Collapse
Affiliation(s)
- Stanley N Caroff
- Department of Psychiatry, Veterans Affairs Medical Center-116A, University & Woodland Avenues, Philadelphia, PA 19104, USA.
| | | | | | | |
Collapse
|
127
|
Pangilinan PH, Giacoletti-Argento A, Shellhaas R, Hurvitz EA, Hornyak JE. Neuropharmacology in Pediatric Brain Injury: A Review. PM R 2010; 2:1127-40. [DOI: 10.1016/j.pmrj.2010.07.007] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2009] [Revised: 06/16/2010] [Accepted: 07/05/2010] [Indexed: 11/28/2022]
|
128
|
Abstract
Drug-induced adverse reactions represent a significant health problem in developed countries. These events cause 5% of hospital admissions and are one of the main causes of mortality. Neurological manifestations are among the most frequent. This article reviews catastrophic cerebrovascular situations and confusional syndromes, as well as epilepsy, structural encephalopathy, neuromuscular disorders, catastrophic movement disorders and infections, all of which can be drug-induced.
Collapse
|
129
|
Patel MK, Brunetti L. Neuroleptic malignant syndrome secondary to aripiprazole initiation in a clozapine-intolerant patient. Am J Health Syst Pharm 2010; 67:1254-9. [PMID: 20651315 DOI: 10.2146/ajhp090243] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
PURPOSE A case of neuroleptic malignant syndrome (NMS) secondary to aripiprazole in a schizophrenic patient previously managed with clozapine is reported. SUMMARY A 42-year-old Caucasian woman with a history of schizophrenia (chronic paranoid type) arrived at the emergency department (ED) with a chief complaint of altered mental status and oliguria. The patient was previously managed with clozapine for 14 years, which was well tolerated until the patient developed urinary retention. As a result, clozapine was gradually discontinued over several weeks. Aripiprazole 30 mg orally once daily was initiated four days before her arrival at the ED. Approximately four days after starting aripiprazole therapy, the patient began experiencing tremors, confusion, and rigidity. Physical examination revealed poor inspiratory effort, diffuse abdominal tenderness, and decreased muscle strength. Initial blood work confirmed acute renal failure and leukocytosis. The patient developed both hypokalemia and hypomagnesemia; her urine myoglobin level was suggestive of rhabdomyolysis. In light of her fever, encephalopathy, autonomic instability, elevated creatine kinase levels, and muscle rigidity, a diagnosis of NMS was made. Supportive care in the form of cooling blankets, electrolyte management, and blood pressure control was provided to the patient. Bromocriptine was also initiated to restore her dopamine balance. Twenty days after the initial presentation, the patient was initiated on paliperidone 3 mg orally at bedtime, which was slowly increased to 9 mg over several weeks. Follow-up evaluation demonstrated no signs or symptoms of NMS. Laboratory test values were also within normal limits. CONCLUSION A 42-year-old Caucasian woman with schizophrenia who could no longer tolerate therapy with clozapine developed NMS secondary to the initiation of aripiprazole.
Collapse
Affiliation(s)
- Mitesh K Patel
- Somerset Family Practice, Somerset Medical Center, Somerville, NJ, USA
| | | |
Collapse
|
130
|
|
131
|
Margetić B, Aukst-Margetić B. Neuroleptic malignant syndrome and its controversies. Pharmacoepidemiol Drug Saf 2010; 19:429-35. [PMID: 20306454 DOI: 10.1002/pds.1937] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
PURPOSE Neuroleptic malignant syndrome (NMS) is a rare and life threatening condition usually defined as a complication of treatment with antipsychotics characterized by severe rigidity, tremor, fever, altered mental status, autonomic dysfunction, and elevated serum creatine phosphokinase and white blood cell count. The literature on this topic is rather extensive, but many aspects related to the syndrome are thought to be controversial. The aim of this paper, written with the clinician in mind, is to summarize some of the most prominent controversies that may have importance in usual clinical practice. METHODS The literature was searched for reviews, reports on the series of cases, individual case reports of NMS, and other clinically and theoretically important information. RESULTS There are controversies associated with virtually all important aspects of NMS. At the moment, it is not clear if this drug reaction is idiosyncratic or not, what diagnostic criteria are the most appropriate for usual clinical practice, and it seems that the estimated incidence is not in accordance with the number of treated patients. There are rather different approaches to the pathophysiological mechanisms, differential diagnosis, and treatment. CONCLUSIONS Some of the controversies related to NMS have an influence on our understanding of the condition and may have importance in clinical practice. There is a need for further research that should elucidate these controversies.
Collapse
|
132
|
Casamassima F, Lattanzi L, Perlis RH, Litta A, Fui E, Bonuccelli U, Fricchione G, Cassano GB. Neuroleptic Malignant Syndrome: Further Lessons From a Case Report. PSYCHOSOMATICS 2010. [DOI: 10.1016/s0033-3182(10)70709-x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
|
133
|
Unaldi M, Sayhan MB, Sogüt O, Demirhan R, Güzel B. Neuroleptic Malignant Syndrome after the Addition of Lithium to Risperidone Treatment: A Case Report and Review of the Literature. HONG KONG J EMERG ME 2010. [DOI: 10.1177/102490791001700317] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Neuroleptic malignant syndrome (NMS) is a rare but life-threatening complication of antipsychotic therapy. The classic features of NMS include muscular rigidity, altered mental status, autonomic instability and hyperthermia. NMS is most often associated with conventional antipsychotic usage. It has also been reported with lithium and antidepressants especially when combined with antipsychotics. Herein, we report a case involving a 35-year-old man with schizoaffective disorder in whom signs and symptoms consistent with NMS developed after lithium was added to his therapy of risperidone. A firm diagnosis of NMS was made on the basis of his history, physical, laboratory and neuroimaging findings. He was then followed up and treated in the intensive care unit with supportive care measures including aggressive cooling, intravenous fluid hydration, nutrition by nasogastric tube and therapy with bromocriptine. The patient had an uneventful clinical course and was discharged from the intensive care unit after three weeks with no complications related to the NMS.
Collapse
Affiliation(s)
- M Unaldi
- Kartal Research and Training Hospital, Department of Emergency Medicine, Istanbul, Turkey
| | | | - O Sogüt
- Harran University School of Medicine, Department of Emergency Medicine, Sanliurfa, Turkey
| | - R Demirhan
- Kartal Research and Training Hospital, Department of Emergency Medicine, Istanbul, Turkey
| | | |
Collapse
|
134
|
Randolph TC. Possible contribution of XYY syndrome to neuroleptic malignant syndrome in a child receiving quetiapine. Am J Health Syst Pharm 2010; 67:459-61. [PMID: 20208052 DOI: 10.2146/ajhp090091] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
PURPOSE A case of early neuroleptic malignant syndrome (NMS) in a child with XYY syndrome after three weeks of quetiapine therapy is reported. SUMMARY A four-year-old, 23-kg boy with a history of oppositional defiant disorder, mood disorder, and XYY syndrome was brought to the emergency care center (ECC) for evaluation secondary to somnolence, gait disturbances, and altered mental status. Three weeks prior, he was started on a daily oral dose of quetiapine 25 mg; this was adjusted upward to 400 mg daily. He had been experiencing episodes of severe confusion, somnolence, and extreme agitation. He was also ataxic and unbalanced on his feet. Upon evaluation at the ECC, he was found to have an elevated creatine kinase (CK) concentration, as well as elevated CK-MB and CK-MM levels, both of which were indicative of skeletal muscle damage. He was slightly diaphoretic and displayed mild rigidity accompanied by varying degrees of agitation and confusion. The diagnosis of NMS secondary to quetiapine therapy was made. Quetiapine was discontinued, and the patient was admitted for observation. His symptoms steadily resolved over the course of his hospital stay, and his total CK levels, as well as CK isoenzyme levels, fell over the course of observation. Quetiapine was not restarted at discharge, and no new medications were prescribed. CONCLUSION A four-year-old boy with XYY syndrome developed signs and symptoms consistent with early NMS after three weeks of quetiapine therapy. High-dose quetiapine, along with possible baseline liver dysfunction secondary to XYY syndrome, may have contributed to the development of NMS in this patient, which resolved after the discontinuation of quetiapine.
Collapse
Affiliation(s)
- Timothy C Randolph
- Pharmacy Services, Carolinas Medical Center--NorthEast, Concord, NC 28025, USA.
| |
Collapse
|
135
|
Abstract
PURPOSE A case study is presented to discuss the importance of accurate assessment of a patient in the emergency department (ED) who develops neuroleptic malignant syndrome (NMS). CONCLUSIONS There has been a significant increase in the number of patients with psychiatric emergencies seeking treatment in the ED. The most frequently used medication for treating these patients is a high-potency typical antipsychotic (neuroleptic). Although NMS is a rare condition, it is a potentially fatal complication of neuroleptic medications. PRACTICE IMPLICATIONS Early identification of this potentially life-threatening syndrome will lead to prompt treatment and improve the care of this vulnerable population.
Collapse
Affiliation(s)
- Lynne Agar
- Rhode Island Hospital, Providence, Rhode Island, USA.
| |
Collapse
|
136
|
Varoglu AO, Ates O, Gundogdu OL, Aksoy A, Deniz O. Zuclopenthixol-induced neuroleptic malignant syndrome presenting as fever of unknown origin, hyperglycaemia and acute myocardial infarction in a 60-year-old man. World J Biol Psychiatry 2010; 10:644-7. [PMID: 17965986 DOI: 10.1080/15622970701714347] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
Neuroleptic malignant syndrome (NMS) is a rare clinical condition and potentially life-threatening complication of antipsychotic medications. We report a patient with an atypical presentation of NMS. A 60-year-old man with schizophrenia was admitted to our hospital with disturbed consciousness, fever and marked extrapyramidal rigidity both in the upper and lower extremities. He had been given i.m. zuclopenthixol 200 mg/month but had not taken the last dose. Laboratory investigations showed that creatinine phosphokinase 428 IU/l (normal up to 130), lactate dehydrogenase 772 IU/l (normal up to 450), blood glucose 256 mg/dl (65-110). Urine analyses revealed ketonuria. White blood cell (WBC) count was 6100 cells/mm(3). Therefore, the patient was diagnosed as having NMS and antipsychotic medications were stopped. Adequate hydration was provided and bromocryptine 5 mg was started three times a day. Despite treatment, the patient died due to acute myocardial infarction after 3 days of hospitalization.
Collapse
|
137
|
Abstract
A 60-year-old woman with a long psychiatric history presented with delirium and mutism. She was febrile, with marked limb rigidity and elevated creatinine kinase (CK) level. Current medications included pericyazine. Current or recent use of dopamine-blocking agents, such as pericyazine, together with a disturbance in conscious state, autonomic dysfunction, and an elevated CK level may be suggestive of neuroleptic malignant syndrome (NMS). The diagnosis was confirmed as NMS, and she was successfully treated with bromocriptine. Eight years later, she represents with symptoms suggesting recurrence of NMS including elevated CK level and myalgia, however, without limb rigidity. Current medications include quetiapine, lithium, simvastatin, and a recent course of clarithromycin. Macrolide antibiotics such as clarithromycin inhibit the metabolic pathway of statins via the cytochrome CYP450 3A4 hepatic enzyme system and may result in elevated CK level, myopathy, or rhabdomyolysis producing symptoms that may be confused with NMS. Simvastatin was ceased with rapid decrease in CK level and resolution of symptoms. This case highlights the importance of considering other diagnoses in any patient presenting with a disturbance in conscious state, autonomic dysfunction, and an elevated CK level. Particularly in a patient with a history of NMS, a thorough medication history is essential to aid diagnosis and avoid confusion with presenting symptoms and medical history.
Collapse
|
138
|
Abstract
El síndrome neuroléptico maligno es una emergencia médica rara, grave y potencialmente fatal, que se asocia al uso de medicamentos neurolépticos, cuya prevalencia es de aproximadamente 0,02% a 3% de los pacientes tratados, y se caracteriza por presentar hipertermia, rigidez muscular, alteración de la conciencia y disautonomía, además de la elevación de la creatinkinasa (CK), aunque muchas veces no es fácil reconocerlo debido a la variedad de diagnósticos diferenciales. La teoría más aceptada es la relacionada con la actividad dopaminérgica en el Sistema Nervioso Central afectando los núcleos de la base y al hipotálamo, por lo que dentro de su tratamiento se encuentra el uso de agonistas dopaminérgicos tales como la bromocriptina, además del resto de medidas generales. La mortalidad resulta directamente de las manifestaciones disautonómicas de la enfermedad y de las complicaciones sistémicas tales como cardiopatías y falla renal aguda secundaria a rabdomiolisis, si no se trata de manera precoz.
Collapse
|
139
|
Stern TA, Celano CM, Gross AF, Huffman JC, Freudenreich O, Kontos N, Nejad SH, Repper-Delisi J, Thompson BT. The assessment and management of agitation and delirium in the general hospital. PRIMARY CARE COMPANION TO THE JOURNAL OF CLINICAL PSYCHIATRY 2010; 12:PCC.09r00938. [PMID: 20582303 PMCID: PMC2882819 DOI: 10.4088/pcc.09r00938yel] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
140
|
Sato T, Nishio H, Iwata M, KentoTsuboi, Tamura A, Miyazaki T, Suzuki K. Postmortem molecular screening for mutations in ryanodine receptor type 1 (RYR1) gene in psychiatric patients suspected of having died of neuroleptic malignant syndrome. Forensic Sci Int 2010; 194:77-9. [DOI: 10.1016/j.forsciint.2009.10.014] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2009] [Revised: 08/20/2009] [Accepted: 10/15/2009] [Indexed: 10/20/2022]
|
141
|
Wait SD, Ponce FA, Killory BD, Wallace D, Rekate HL. Neuroleptic malignant syndrome from central nervous system insult: 4 cases and a novel treatment strategy. Clinical article. J Neurosurg Pediatr 2009; 4:217-21. [PMID: 19772404 DOI: 10.3171/2009.4.peds08444] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Neuroleptic malignant syndrome (NMS) is a potentially life-threatening entity characterized by hyperthermia, autonomic deregulation, decreased mental status, increased muscle tone, and, frequently, by renal failure due to rhabdomyolysis. Classically, it follows administration of antipsychotic medication. The authors report on 4 patients (2 children and 2 adults) in whom NMS was diagnosed after a CNS insult. No patient was receiving antipsychotic medication. The patients' hospital and clinic charts, radiographic data, and follow-up telephone conversations were reviewed retrospectively. All 4 patients met diagnostic criteria for NMS. Three patients presented with shunt failure, and 1 patient had undergone a functional hemispherectomy 2 days earlier. One patient with shunt failure received the diagnosis retrospectively. An endoscopic third ventriculostomy alleviated his shunt failure and he remains free of NMS. The other 2 patients underwent treatment for shunt failure, but NMS remained. These 2 patients and the one who had undergone hemispherectomy underwent a trial of intrathecal baclofen, and the NMS resolved. Subsequently, an intrathecal baclofen infusion device was placed in all 3 patients, and the NMS resolved. The 2 patients in shunt failure had a lumbar intrathecal baclofen infusion device. The patient who had undergone hemispherectomy had an intracranial baclofen catheter. Neuroleptic malignant syndrome is a rare, life-threatening disorder that can occur without the administration of neuroleptic medications. Alleviation of any CNS insult is the first order of treatment. Some patients with persistent symptoms of NMS may benefit from intrathecal delivery of baclofen.
Collapse
Affiliation(s)
- Scott D Wait
- Divisions of Neurological Surgery, Barrow Neurological Institue, St. Joseph's Hospital and Medical Center, Phoenix, Arizona 85013, USA
| | | | | | | | | |
Collapse
|
142
|
Abstract
Neuroleptic malignant syndrome (NMS) is a rare but potentially severe idiosyncratic adverse reaction usually seen in the context of treatment with antipsychotic drugs. Although NMS is historically associated with the classic or 'typical' antipsychotic drugs, it is also a potential adverse effect of atypical antipsychotic drugs. The widespread use of atypical antipsychotic drugs highlights the need to examine the data relating to the symptomatology, diagnosis, classification and management of NMS with these newer agents. We used MEDLINE and EMBASE to identify NMS case reports and systematic reviews published to June 2008 related to the atypical antipsychotic drugs clozapine, olanzapine, risperidone, paliperidone, aripiprazole, ziprasidone, amisulpride and quetiapine. Case reports and reviews were systematically examined. Our review suggests that, in general, NMS associated with atypical antipsychotic drugs manifests in a typical manner. One notable exception is clozapine-induced NMS, which appears less likely to manifest with extrapyramidal features, including rigidity and tremor. The available literature highlights the divergence of opinion relating to the core diagnostic features of NMS and its conceptualization as a categorical versus dimensional disorder. Both these issues have relevance for the identification of atypical or milder forms of NMS, which are sometimes seen with atypical antipsychotic drugs.
Collapse
Affiliation(s)
- Julian N Trollor
- School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia.
| | | | | |
Collapse
|
143
|
Ulger F, Dilek A, Karakaya D, Senel A, Sarihasan B. Fatal fever of unknown origin in acute cervical spinal cord injury: five cases. J Spinal Cord Med 2009; 32:343-8. [PMID: 19810636 PMCID: PMC2718819 DOI: 10.1080/10790268.2009.11760788] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
Abstract
BACKGROUND/OBJECTIVE Patients with traumatic upper thoracic and cervical spinal cord injuries are at increased risk for the development of autonomic dysfunction, including thermodysregulation. Thermoregulation is identified as an autonomic function, although the exact mechanisms of thermodysregulation have not been completely recognized. Quad fever is a hyperthermic thermoregulatory disorder that occurs in people with acute cervical and upper thoracic spinal cord injuries. First described in 1982, it has not been widely discussed in the literature. METHODS Case reports of 5 patients with cervical spinal cord injury (SCI). RESULTS Five of 18 patients (28%) with acute cervical SCI who were admitted during a 1-year period had fatal complications caused by persistent hyperthermia of unknown origin. CONCLUSIONS Patients with acute traumatic cervical and upper thoracic SCI are at risk for thermoregulatory dysfunction. Changes in the hypothalamic axis may be implicated, especially in the light of modification in hypothalamic afferent nerves, but this hypothesis has not yet been explored. Thermodysregulation may be an early sign of autonomic dysfunction. A comprehensive guideline is needed for the management of elevated body temperature in critically ill patients with cervical SCI, because this condition may be fatal.
Collapse
Affiliation(s)
- Fatma Ulger
- 1Department of Anesthesiology and Reanimation, 2Department of Neurosurgery Ondokuz Mayis University, Kurupelit, Samsun, Turkey
| | - Ahmet Dilek
- 1Department of Anesthesiology and Reanimation, 2Department of Neurosurgery Ondokuz Mayis University, Kurupelit, Samsun, Turkey
| | - Deniz Karakaya
- 1Department of Anesthesiology and Reanimation, 2Department of Neurosurgery Ondokuz Mayis University, Kurupelit, Samsun, Turkey
| | - Alparslan Senel
- 1Department of Anesthesiology and Reanimation, 2Department of Neurosurgery Ondokuz Mayis University, Kurupelit, Samsun, Turkey
| | - Binnur Sarihasan
- 1Department of Anesthesiology and Reanimation, 2Department of Neurosurgery Ondokuz Mayis University, Kurupelit, Samsun, Turkey
| |
Collapse
|
144
|
Kuchibatla SS, Cheema SA, Chakravarthy KS, Sayeh HGE. A case report of neuroleptic malignant syndrome. BMJ Case Rep 2009; 2009:bcr07.2008.0429. [PMID: 21686818 DOI: 10.1136/bcr.07.2008.0429] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Abstract
A 32-year-old male patient with a history of treatment resistant paranoid schizophrenia developed neuroleptic malignant syndrome (NMS) during changeover of his antipsychotic medication from zuclopenthixol depot to clozapine. This case highlights the difficulties of cross-tapering two antipsychotics-that is, converting from a typical depot medication to an oral atypical antipsychotic.
Collapse
Affiliation(s)
- Shankar Srinivas Kuchibatla
- North Yorkshire and York PCT, Psychiatry, Briary Wing, Harrogate District Hospital, Lancaster Park Road, Harrogate HG2 7SX, UK
| | | | | | | |
Collapse
|
145
|
Seitz DP, Gill SS. Neuroleptic malignant syndrome complicating antipsychotic treatment of delirium or agitation in medical and surgical patients: case reports and a review of the literature. PSYCHOSOMATICS 2009; 50:8-15. [PMID: 19213967 DOI: 10.1176/appi.psy.50.1.8] [Citation(s) in RCA: 47] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
BACKGROUND Neuroleptic malignant syndrome (NMS) is a potentially fatal adverse event associated with the use of antipsychotics. OBJECTIVE The authors provide information on the development and outcome of NMS during antipsychotic treatment of delirium or agitation in medically ill patients. METHOD The authors present case reports and a literature review of NMS arising during antipsychotic treatment of delirium. RESULTS A total of 25 cases of NMS occurring in patients with delirium or agitation were identified. Most cases involved men with agitated delirium who received relatively high doses of parenteral haloperidol. The signs and symptoms of NMS episodes were similar to those reported in other settings, and most patients had a complete recovery. CONCLUSION Clinicians utilizing antipsychotics in managing delirium or agitation are advised to be vigilant for NMS. Further study is required to determine whether certain patient characteristics or medications present greater risk for this serious adverse event.
Collapse
Affiliation(s)
- Dallas P Seitz
- Department of Psychiatry, Queen's University, Kingston, Ontario, Canada.
| | | |
Collapse
|
146
|
Dan A, Bharadwaj R, Grover S. Neuroleptic malignant syndrome with use of quetiapine in mental retardation. Psychiatry Clin Neurosci 2009; 63:255-6. [PMID: 19335404 DOI: 10.1111/j.1440-1819.2008.01921.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
147
|
Vurucu S, Congologlu A, Altun D, Unay B, Akin R. Neuroleptic malignant syndrome due to risperidone treatment in a child with Joubert syndrome. J Natl Med Assoc 2009; 101:273-5. [PMID: 19331262 DOI: 10.1016/s0027-9684(15)30858-0] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
Joubert syndrome is a rare autosomal recessive disease characterized by hypotonia, ataxia, episodic hyperpnea, psychomotor retardation, abnormal ocular movements, cerebellar vermian hypoplasia, and molar tooth sign on magnetic resonance imaging. Neuroleptic malignant syndrome is an uncommon and potentially fatal idiosynchratic reaction of antipsychotic drugs, in which the clinical scenario encompass muscular rigidity, hyperthermia, autonomic dysfunction, altered consciousness, high creatinine phosphokinase levels, and leukocytosis. This report describes a case of neuroleptic malignant syndrome due to risperidone in a child with Joubert syndrome.
Collapse
Affiliation(s)
- Sebahattin Vurucu
- Department of Pediatrics, Gulhane Military Medical Academy, Ankara, Turkey.
| | | | | | | | | |
Collapse
|
148
|
Gortney JS, Fagan A, Kissack JC. Neuroleptic Malignant Syndrome Secondary to Quetiapine. Ann Pharmacother 2009; 43:785-91. [DOI: 10.1345/aph.1l371] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Abstract
Objective: To report a case of neuroleptic malignant syndrome (NMS) secondary to quetiapine in which the patient developed extrapyramidal symptoms (EPS). Case Summary: A 34-year-old male with a history of severe brain damage, mental retardation, and seizures was admitted to the hospital with changes in mental status, development of tremors, and a temperature of 39.9 °C. Initial differentia) diagnoses included seizure, aspiration, stroke, and infection. Once these were excluded, NMS was considered. The patient exhibited other characteristics of NMS during hospitalization, including lead pipe rigidity, tachycardia, and high creatine kinase level (up to 12,654 IU/L). Drug therapy on presentation included quetiapine 200 mg 3 times per day, guanfacine 2 mg/day. carbamazepine 400 mg every 12 hours, valproic acid 500 mg twice daily, and lorazepam 2 mg (unknown schedule). He reportedly had received these medications for at least a month before admission. On hospital day 2, quetiapine was discontinued. The patient received traditional treatment (or NMS, which included bromocriptine, dantrolene, intravenous fluids, and supportive care. The NMS resolved in 7 days. Discussion: In cases of NMS, clinicians previously believed that the risk for developing severe adverse effects such as EPS was lower with atypical versus typical antipsychotics. We identified 13 cases of NMS secondary to quetiapine in the literature via a search of MEDLINE/PubMed (1950–2008), and Iowa Drug Information Service (1966–2008). Seventy-five percent of previous reports of NMS secondary to quetiapine had reactions that included EPS, Common patient characteristics in our report and others included male sex, history of mental retardation, and treatment modalities used in NMS. Unique characteristics in this case included length of therapy without dosage change or titration and no known history of drug-related EPS. The Naranjo probability scale indicated a probable relationship between the development of NMS and quetiapine. Conclusions: NMS with associated EPS has been previously associated with quetiapine. Clinicians should be aware that NMS with EPS can occur with quetiapine at steady state doses without recent dosage adjustments or titration.
Collapse
Affiliation(s)
| | - Alexandria Fagan
- Department of Pharmacy, Centennial Medical Center, Nashville, TN
| | | |
Collapse
|
149
|
Srivastava A, Borkar HA, Chandak S. Olanzapine-induced neuroleptic malignant syndrome in a patient with paranoid schizophrenia. Psychiatry Clin Neurosci 2009; 63:119-21. [PMID: 19067992 DOI: 10.1111/j.1440-1819.2008.01894.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
A case of a male patient with schizophrenic illness who developed neuroleptic malignant syndrome (NMS) following treatment with olanzapine is reported. Although typical neuroleptics are more frequently associated with NMS, atypical antipsychotics may also cause NMS. Case reports have been published concerning NMS and clozapine,(1) risperidone(2) and olanzapine.(3-6) This case report emphasizes the importance of being cautious when rapidly increasing doses of olanzapine are used in patients with psychiatric illnesses.
Collapse
|
150
|
Abstract
Movement disorder emergencies include any movement disorder which evolves over hours to days, in which failure to appropriately diagnose and manage can result in patient morbidity or mortality. It is crucial that doctors recognize these emergencies with accuracy and speed by obtaining the proper history and by being familiar with the phenomenology of frequently encountered movements. These disorders will be discussed based on the most common associated involuntary movement, either parkinsonism, dystonia, chorea, tics or myoclonus, and, when available, review the workup and treatment options based on the current literature.
Collapse
|